Organigram (OGI) Competitors

Merrimack Pharmaceuticals (NASDAQ:MACK) and Organigram (NASDAQ:OGI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, community ranking, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

Which has more volatility and risk, MACK or OGI?

Merrimack Pharmaceuticals has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500. Comparatively, Organigram has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500.

Which has stronger earnings & valuation, MACK or OGI?

Merrimack Pharmaceuticals has higher earnings, but lower revenue than Organigram. Merrimack Pharmaceuticals is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Merrimack Pharmaceuticals	N/A	N/A	-$1.18M	-$0.08	-183.63
Organigram	$120.01M	1.64	-$184.34M	-$0.80	-2.39

Does the media favor MACK or OGI?

In the previous week, Organigram had 2 more articles in the media than Merrimack Pharmaceuticals. MarketBeat recorded 3 mentions for Organigram and 1 mentions for Merrimack Pharmaceuticals. Merrimack Pharmaceuticals' average media sentiment score of 0.50 beat Organigram's score of -0.36 indicating that Organigram is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Merrimack Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Organigram	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor MACK or OGI?

Merrimack Pharmaceuticals received 203 more outperform votes than Organigram when rated by MarketBeat users. However, 70.61% of users gave Organigram an outperform vote while only 67.00% of users gave Merrimack Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Merrimack Pharmaceuticals	Outperform Votes 400 67.00%	Underperform Votes 197 33.00%
Organigram	Outperform Votes 197 70.61%	Underperform Votes 82 29.39%

Do institutionals and insiders hold more shares of MACK or OGI?

64.0% of Merrimack Pharmaceuticals shares are owned by institutional investors. Comparatively, 34.6% of Organigram shares are owned by institutional investors. 28.9% of Merrimack Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Organigram shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Is MACK or OGI more profitable?

Merrimack Pharmaceuticals has a net margin of 0.00% compared to Merrimack Pharmaceuticals' net margin of -173.48%. Organigram's return on equity of -6.24% beat Merrimack Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Merrimack Pharmaceuticals	N/A	-6.24%	-6.09%
Organigram	-173.48%	-30.94%	-27.70%

Do analysts prefer MACK or OGI?

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Merrimack Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Organigram	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Merrimack Pharmaceuticals beats Organigram on 9 of the 15 factors compared between the two stocks.